TY - JOUR
T1 - A clinicopathological description of COVID-19-induced chilblains (COVID-toes) correlated with a published literature review
AU - Kolivras, Athanassios
AU - Thompson, Curtis
AU - Pastushenko, Ievgenia
AU - Mathieu, Marisa
AU - Bruderer, Pascal
AU - de Vicq, Marine
AU - Feoli, Francesco
AU - Harag, Saadia
AU - Meiers, Isabelle
AU - Olemans, Catherine
AU - Sass, Ursula
AU - Dehavay, Florence
AU - Fakih, Ali
AU - Lam-Hoai, Xuan-Lan
AU - Marneffe, Alice
AU - Van De Borne, Laura
AU - Vandersleyen, Valerie
AU - Richert, Bertrand
PY - 2022/1
Y1 - 2022/1
N2 - Background The abundance of publications of COVID-19-induced chilblains has resulted in a confusing situation. Methods This is a prospective single-institution study from 15 March to 13 May 2020. Thirty-two patients received PCR nasopharyngeal swabs. Of these, 28 patients had a thoracic CT-scan, 31 patients had blood and urine examinations, 24 patients had skin biopsies including immunohistochemical and direct immunofluorescence studies, and four patients had electron microscopy. Results COVID-19-induced chilblains are clinically and histopathologically identical to chilblains from other causes. Although intravascular thrombi are sometimes observed, no patient had a systemic coagulopathy or severe clinical course. The exhaustive clinical, radiological, and laboratory work-up in this study ruled-out other primary and secondary causes. Electron microscopy revealed rare, probable viral particles whose core and spikes measured from 120 to 133 nm within endothelium and eccrine glands in two cases. Conclusion This study provides further clinicopathologic evidence of COVID-19-related chilblains. Negative PCR and antibody tests do not rule-out infection. Chilblains represent a good prognosis, occurring later in the disease course. No systemic coagulopathy was identified in any patient. Patients presenting with acral lesions should be isolated, and chilblains should be distinguished from thrombotic lesions (livedo racemosa, retiform purpura, or ischemic acral necrosis).
AB - Background The abundance of publications of COVID-19-induced chilblains has resulted in a confusing situation. Methods This is a prospective single-institution study from 15 March to 13 May 2020. Thirty-two patients received PCR nasopharyngeal swabs. Of these, 28 patients had a thoracic CT-scan, 31 patients had blood and urine examinations, 24 patients had skin biopsies including immunohistochemical and direct immunofluorescence studies, and four patients had electron microscopy. Results COVID-19-induced chilblains are clinically and histopathologically identical to chilblains from other causes. Although intravascular thrombi are sometimes observed, no patient had a systemic coagulopathy or severe clinical course. The exhaustive clinical, radiological, and laboratory work-up in this study ruled-out other primary and secondary causes. Electron microscopy revealed rare, probable viral particles whose core and spikes measured from 120 to 133 nm within endothelium and eccrine glands in two cases. Conclusion This study provides further clinicopathologic evidence of COVID-19-related chilblains. Negative PCR and antibody tests do not rule-out infection. Chilblains represent a good prognosis, occurring later in the disease course. No systemic coagulopathy was identified in any patient. Patients presenting with acral lesions should be isolated, and chilblains should be distinguished from thrombotic lesions (livedo racemosa, retiform purpura, or ischemic acral necrosis).
KW - chilblains
KW - coagulation
KW - coagulopathy
KW - COVID-19
KW - COVID-toes
KW - CT-scan
KW - direct immunofluorescence study
KW - electron microscopy
KW - histopathology
KW - hypercoagulable
KW - immunohistochemistry
KW - interferon
KW - livedo racemosa
KW - lupus erythematosus
KW - paraviral
KW - retiform purpura
KW - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
KW - thrombi
UR - http://www.scopus.com/inward/record.url?scp=85112609931&partnerID=8YFLogxK
U2 - 10.1111/cup.14099
DO - 10.1111/cup.14099
M3 - Book/Film/Article review
C2 - 34272741
VL - 49
SP - 17
EP - 28
JO - Journal of cutaneous pathology
JF - Journal of cutaneous pathology
SN - 0303-6987
IS - 1
ER -